Furthermore, follow-up results from the CheckMate 025 trial showed that PBRM1 mutations were strongly associated with improved PFS and OS in advanced ccRCC patients treated with nivolumab, which was not observed in the everolimus group (140, 141). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.